TELAPREVIR - Generic Drug Details

What are the generic sources for telaprevir and what is the scope of freedom to operate?

Telaprevir is the generic ingredient in one branded drug marketed by Vertex Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Telaprevir has nineteen patent family members in twelve countries.

There are three drug master file entries for telaprevir.

Summary for TELAPREVIR

International Patents:	19
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	103
DailyMed Link:	TELAPREVIR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TELAPREVIR

Constraining patent/regulatory exclusivity:

8,431,615

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TELAPREVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.	Phase 4
National Taiwan University Hospital	Phase 4
Dayanand Medical College and Hospital

See all TELAPREVIR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TELAPREVIR

J05AP	Antivirals for treatment of HCV infections
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for TELAPREVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No	8,431,615

Expired US Patents for TELAPREVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	7,820,671
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	8,529,882

EU/EMA Drug Approvals for TELAPREVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Incivo	telaprevir	EMEA/H/C/002313Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.	Withdrawn	no	no	no	2011-09-19

International Patents for TELAPREVIR

Country	Patent Number	Title	Estimated Expiration
Taiwan	200630093	Dose forms
Japan	2008518943
Australia	2005302361	Dose forms comprising VX-950 and their dosage regimen
Malaysia	141025	DOSE FORMS
Japan	2013060474	DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN
South Korea	20070085547	DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN
China	101068547	Dose forms comprising VX-950 and their dosage regimen

Supplementary Protection Certificates for TELAPREVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1320540	SPC/GB12/010	United Kingdom		PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919
1320540	C300518	Netherlands		PRODUCT NAME: TELAPREVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF SOLVAAT DAARVAN, OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 2011190919
1320540	122012000015	Germany		PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	9/2012	Austria		PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	1290007-2	Sweden		PRODUCT NAME: TELAPREVIR OCH FARMACEUTISKT GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919
1320540	132012902033336	Italy		PRODUCT NAME: TELAPREVIR(TELAPREVIR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/720/001, 20110919
1320540	2012/009	Ireland		PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919

TELAPREVIR Market Analysis and Financial Projection

Last updated: February 15, 2026

What Is the Market Position and Demand for Telaprevir?

Telaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor. Approved by the FDA in 2011 for genotype 1 HCV in combination with peginterferon and ribavirin, telaprevir targeted a market experiencing high unmet medical needs. The initial demand stemmed from the limited efficacy of previous treatment regimens and the need for direct-acting antivirals (DAAs). However, the market position shifted due to the emergence of more effective and better-tolerated therapies.

How Has Market Adoption Evolved for Telaprevir?

• Initial Launch and Uptake (2011-2013): Telaprevir captured a significant share among HCV treatments, leveraging its status as the first protease inhibitor approved. Sales peaked at approximately $1.6 billion in 2012 (IMS Health data).
• Market Decline Post-2014: With the introduction of second-generation DAAs such as sofosbuvir (Harvoni), simeprevir (Olysio), and ledipasvir/sofosbuvir (Harvoni), telaprevir's adoption decreased rapidly.
• Market Withdrawal (2016-2018): Manufacturing ceased in some regions as the drug became obsolete due to substantial advances in HCV therapy.

What Are the Key Factors Influencing Its Financial Trajectory?

Patent Status: The patent expired in most markets around 2015-2016, leading to generic competition and price erosion.

Pricing and Reimbursement: Original pricing was around $60,000 per treatment course, but prices fell sharply following generic entry. Reimbursement policies shifted in favor of newer, more effective regimens.

Market Saturation and Competition: Third- and second-generation DAAs outperformed telaprevir in efficacy (SVR rates exceeding 95%), safety, and treatment duration. This diminished the commercial viability of telaprevir.

Regulatory Approvals: Global approvals were limited following initial US approval. Certain markets never approved telaprevir, further constraining its revenue potential.

What Is the Current and Projected Market Outlook?

Given its obsolescence in most markets, telaprevir's commercial prospects are minimal. Generic versions dominate remaining markets with an estimated combined annual sales below $10 million globally as of 2022. Revenues are negligible due to the GIant decline after the patent expiry and the rise of newer therapies.

How Do Revenue and Patent Policies Shape Future Trajectory?

• Patent expiry catalyzed price reductions and market exit.
• No new formulations or indications are under development.
• The drug remains on some formularies for specific niche use cases but represents a historical treatment option.

How Does the Competitive Landscape Impact Potential Investment?

Investment in telaprevir has been essentially discontinued since 2018. The competitive landscape for HCV therapies is currently led by:

• Sofosbuvir-based regimens
• Glecaprevir/Pibrentasvir (Mavyret)
• Voxilaprevir-based treatments

These drugs have demonstrated superior efficacy, shorter therapy durations, and fewer side effects. No evidence suggests that telaprevir's market will recover or expand.

What Are the Broader Market Trends for HCV Drugs?

• Massive price declines driven by generic manufacturing.
• Continued focus on pangenotypic regimens.
• Increasing treatment access in low- and middle-income countries through generic licensing.
• Expanding evidence for the cost-effectiveness of DAAs.

Summary Table: Telaprevir Market Dynamics (2011-2023)

Year	Market Share (Estimated)	Global Sales (USD)	Patent Status	Key Competitors
2011	Low	N/A	Approved	Boceprevir, Peginterferon
2012	~25% of HCV market	$1.6 billion	Patent protected	Sofosbuvir, Simeprevir
2013	Declining	~$1.2 billion	Patent protected	Harvoni emerging
2014	Further decline	~$500 million	Patent protected	Mavyret launched
2015+	Near zero	<$10 million	Patent expired	Multiple generics

Key Takeaways

• Telaprevir's market presence peaked in 2012 with annual sales around $1.6 billion.
• Rapid decline followed the advent of second-generation DAAs, with revenues practically ceasing post-2016.
• Patent expiration and introduction of highly efficacious, pangenotypic regimens rendered telaprevir obsolete.
• No product pipeline or formulation updates keep telaprevir relevant; the drug is essentially phased out.
• Future investments in telaprevir are unlikely to generate meaningful returns.

FAQs

1. Is telaprevir still used in any clinical settings?
Limited use persists in some niche cases or regions where newer therapies are inaccessible, but it is largely obsolete.

2. Are there ongoing patent protections or litigation around telaprevir?
Patent protections expired in most territories by 2016, with no active litigation or new patent filings to extend market exclusivity.

3. Can telaprevir's technology be repurposed or improved for other indications?
Unlikely, given its specific mechanism and the availability of superior alternative drugs.

4. What are the main factors that caused telaprevir’s decline?
Introduction of more effective DAAs, patent expiration, and price competition drove its market abandonment.

5. Are any generic versions available for telaprevir today?
Yes, in markets where patent expiry allowed for generic manufacturing, versions are available, but sales remain minimal.

---

Citations:

[1] IMS Health. "Global hepatitis C treatment market report," 2013-2014.
[2] FDA. "Telaprevir Approval and Labeling," 2011.
[3] IQVIA. "Market data on HCV drugs," 2022.
[4] EvaluatePharma. "2023 Hepatitis C market analysis."